Sera Prognostics Raises $1.4M to Fund Development of Protein Biomarker Test for Preterm Births

In recent studies, the test, which the company hopes to bring to market by the end of the year, has demonstrated sensitivity as high as 94 percent and specificity as high as 85 percent, said an official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.